

Claims

1. An Fc fragment as a drug carrier, which is an IgG Fc, a combination thereof or a hybrid thereof.

2. The Fc fragment as set forth in claim 1, wherein  
5 the IgG is IgG2 or IgG4.

3. The Fc fragment as set forth in claim 2, wherein the IgG is IgG4.

4. The Fc fragment as set forth in claim 1, which is aglycosylated.

10 5. The Fc fragment as set forth in claim 4, which is an aglycosylated IgG4 Fc fragment.

6. The Fc fragment as set forth in claim 5, which is a human-derived aglycosylated IgG4 Fc fragment.

7. The Fc fragment as set forth in claim 1, which has  
15 an amino acid sequence represented by SEQ ID NO. 8, 10 or 23.

8. A gene encoding the Fc fragment of claim 1.

9. The gene as set forth in claim 8, which has a nucleotide sequence represented by SEQ ID NO. 4, 9 or 22.

10. A recombinant vector comprising the nucleotide sequence of claim 9.

5 11. A transformant transformed with the recombinant vector of claim 10.

12. A method of preparing an Fc fragment, comprising culturing the transformed microorganism of claim 11.

10 13. A pharmaceutical composition comprising the Fc fragment of claim 1.